Lab
Sutter Bay Hospitals
Sutter Bay Hospitals was paid $43.78M by Medicaid between Mar 2018 and Dec 2024, across 266 billing codes. Its largest line is 0112, — 8.1% of everything it billed.
33Billing provider infoSUTTER BAY HOSPITALS
BERKELEY, CA 94705
BERKELEY, CA 94705
33aNPI1639523004assigned 04/21/2016
33bProvider typeClinical Medical Laboratory
28Total paid$43.78M
24GClaims722,800
24DCodes billed266
24AFirst – last monthMar 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#24 of 561
Median peer was paid$222K
This provider vs. median197×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official GATES, JOHN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 101,140 | $6.45M | |
| 2019 | 113,382 | $9.06M | |
| 2020 | 92,412 | $5.05M | |
| 2021 | 100,194 | $4.89M | |
| 2022 | 91,376 | $4.85M | |
| 2023 | 109,123 | $6.84M | |
| 2024incomplete | 115,173 | $6.65M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0112 | 8.1% | 301 | 289 | $3.55M | |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.4% | 37,146 | 32,131 | $3.22M |
| 0121 | 4.1% | 229 | 222 | $1.78M | |
| 80053 | Comprehensive metabolic panel | 3.9% | 51,818 | 43,037 | $1.71M |
| 77386 | 3.8% | 747 | 72 | $1.65M | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.0% | 4,157 | 4,029 | $1.31M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.9% | 13,635 | 12,198 | $1.28M |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 2.8% | 13,656 | 8,758 | $1.24M |
| 0450 | Emergency room services | 2.8% | 17,595 | 15,581 | $1.22M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.7% | 4,847 | 4,642 | $1.19M |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | 2.7% | 19,368 | 14,393 | $1.17M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.4% | 8,274 | 6,174 | $1.05M |
254 more codes
| 99199 | Unlisted special service, procedure or report | 2.4% | 10,711 | $1.03M |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.0% | 12,847 | $878K |
| 0250 | 1.8% | 4,158 | $793K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 19,293 | $744K |
| J3490 | Unclassified drugs | 1.6% | 23,111 | $695K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 7,066 | $661K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.3% | 10,512 | $560K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 55,402 | $554K |
| 59025 | Fetal non-stress test | 1.2% | 11,402 | $517K |
| 0360 | 1.1% | 1,050 | $503K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 1,782 | $494K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 1.1% | 3,553 | $489K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.1% | 3,383 | $482K |
| 77334 | 1.1% | 1,303 | $478K | |
| 0721 | <1% | 311 | $432K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 8,721 | $430K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 5,178 | $425K |
| 82077 | <1% | 4,032 | $419K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,859 | $410K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,805 | $399K |
| 99070 | <1% | 13,725 | $386K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,177 | $374K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,679 | $348K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 4,037 | $343K |
| 77336 | <1% | 3,332 | $341K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 2,018 | $324K |
| 76801 | <1% | 3,468 | $312K | |
| 76830 | Ultrasound, transvaginal | <1% | 3,148 | $306K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,676 | $298K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,060 | $282K |
| 77412 | <1% | 2,614 | $282K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,070 | $273K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,755 | $231K |
| 0510 | <1% | 5,068 | $230K | |
| 93971 | <1% | 1,551 | $227K | |
| 71045 | Radiologic examination, chest; single view | <1% | 11,411 | $219K |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 3,878 | $213K |
| 77300 | <1% | 497 | $209K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,554 | $204K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 662 | $187K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,048 | $171K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,055 | $170K |
| 0301 | <1% | 874 | $165K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,902 | $162K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,006 | $155K |
| 99283 | Emergency room visit (moderate) | <1% | 2,468 | $149K |
| 84484 | <1% | 12,750 | $140K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 11,630 | $133K |
| 0710 | <1% | 686 | $133K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,552 | $128K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,072 | $128K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 416 | $116K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 591 | $113K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,704 | $108K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 266 | $106K |
| 0272 | <1% | 521 | $103K | |
| 83690 | <1% | 11,757 | $99K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,723 | $98K |
| J0475 | Injection, baclofen, 10 mg | <1% | 86 | $98K |
| 83880 | <1% | 2,722 | $97K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 658 | $93K |
| 84702 | <1% | 5,722 | $90K | |
| J2323 | Injection, natalizumab, 1 mg | <1% | 40 | $85K |
| 97139 | <1% | 3,249 | $82K | |
| 0171 | Inj, epinephrine (belcher) | <1% | 152 | $77K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,802 | $75K |
| 99285 | Emergency room visit (most serious) | <1% | 895 | $72K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,382 | $70K |
| 86803 | <1% | 3,757 | $70K | |
| 96367 | <1% | 1,173 | $70K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,789 | $69K |
| 81001 | <1% | 16,360 | $66K | |
| 0305 | <1% | 850 | $66K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 763 | $66K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,955 | $65K |
| 86703 | <1% | 3,804 | $61K | |
| 77301 | <1% | 55 | $59K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 531 | $59K |
| Z7500 | <1% | 1,588 | $54K | |
| 80143 | <1% | 406 | $54K | |
| 96417 | <1% | 1,008 | $53K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,274 | $52K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,213 | $51K |
| 87040 | <1% | 4,062 | $51K | |
| 94726 | <1% | 785 | $51K | |
| 0302 | <1% | 623 | $51K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,672 | $50K |
| 93798 | <1% | 1,231 | $49K | |
| 73030 | <1% | 1,303 | $49K | |
| 73630 | <1% | 1,396 | $49K | |
| 94729 | <1% | 881 | $47K | |
| 80179 | <1% | 369 | $47K | |
| 83735 | <1% | 6,094 | $45K | |
| 83605 | <1% | 3,600 | $45K | |
| 84703 | <1% | 6,306 | $45K | |
| 0370 | <1% | 150 | $43K | |
| 73562 | <1% | 1,246 | $43K | |
| 96415 | <1% | 846 | $42K | |
| 73610 | <1% | 1,034 | $41K | |
| 93970 | <1% | 183 | $40K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 411 | $39K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,391 | $39K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,840 | $38K |
| Z9725 | <1% | 836 | $36K | |
| 0306 | <1% | 600 | $35K | |
| 0460 | <1% | 58 | $33K | |
| 0258 | <1% | 691 | $33K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 630 | $32K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 274 | $31K |
| 72100 | <1% | 735 | $30K | |
| 76770 | <1% | 318 | $30K | |
| 77387 | <1% | 96 | $29K | |
| 81025 | <1% | 4,285 | $29K | |
| 94060 | <1% | 408 | $29K | |
| 82731 | <1% | 467 | $27K | |
| 0402 | <1% | 206 | $27K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 79 | $26K |
| 85610 | <1% | 5,717 | $25K | |
| 77338 | <1% | 87 | $24K | |
| 86850 | <1% | 3,374 | $23K | |
| 85730 | <1% | 3,278 | $22K | |
| 0750 | <1% | 119 | $22K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,657 | $21K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,825 | $21K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,266 | $20K |
| 87077 | <1% | 2,108 | $20K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,479 | $20K |
| 73130 | <1% | 546 | $20K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 966 | $20K |
| 86900 | <1% | 5,681 | $19K | |
| 81003 | <1% | 6,526 | $19K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,033 | $19K |
| 86901 | <1% | 4,933 | $19K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 411 | $18K |
| 94010 | <1% | 528 | $18K | |
| 82947 | <1% | 2,588 | $18K | |
| 73502 | <1% | 364 | $17K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 560 | $17K |
| 0324 | <1% | 218 | $17K | |
| 93017 | <1% | 183 | $16K | |
| 87186 | <1% | 1,734 | $16K | |
| 85379 | <1% | 1,282 | $16K | |
| 87081 | <1% | 1,615 | $16K | |
| 95990 | <1% | 132 | $14K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 14 | $14K |
| 80047 | <1% | 974 | $13K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,565 | $13K |
| 97750 | <1% | 294 | $13K | |
| 90715 | <1% | 240 | $13K | |
| 76536 | <1% | 158 | $12K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,329 | $12K |
| 87210 | <1% | 2,118 | $12K | |
| 0270 | <1% | 322 | $11K | |
| 86923 | <1% | 117 | $11K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 19 | $11K |
| 0760 | <1% | 181 | $11K | |
| 0949 | <1% | 231 | $11K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 401 | $11K |
| 83615 | <1% | 2,031 | $10K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 283 | $10K |
| 82570 | <1% | 1,466 | $10K | |
| 77290 | <1% | 44 | $7K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 166 | $7K |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,149 | $7K |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 382 | $7K |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 76 | $7K |
| 0730 | <1% | 216 | $6K | |
| 77280 | <1% | 63 | $6K | |
| 0352 | <1% | 16 | $6K | |
| 84439 | <1% | 352 | $6K | |
| 84156 | <1% | 1,440 | $6K | |
| 96402 | <1% | 163 | $6K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 711 | $6K |
| J1815 | Injection, insulin, per 5 units | <1% | 90 | $6K |
| 76818 | <1% | 217 | $6K | |
| 76820 | <1% | 193 | $6K | |
| 99201 | <1% | 83 | $6K | |
| 82728 | <1% | 774 | $6K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 164 | $5K |
| 84100 | <1% | 1,118 | $5K | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 133 | $5K |
| 96376 | <1% | 106 | $4K | |
| 73110 | <1% | 109 | $4K | |
| 93975 | <1% | 13 | $4K | |
| 72040 | <1% | 99 | $4K | |
| 84550 | <1% | 729 | $4K | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 118 | $4K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 180 | $4K |
| 72131 | <1% | 12 | $4K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 75 | $4K |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 302 | $4K |
| 85027 | <1% | 511 | $4K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 49 | $4K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 258 | $3K |
| 85014 | <1% | 1,209 | $3K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 163 | $3K |
| 70496 | <1% | 15 | $3K | |
| 0307 | <1% | 372 | $3K | |
| 94644 | <1% | 89 | $3K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 85 | $3K |
| 86592 | <1% | 311 | $3K | |
| 77417 | <1% | 28 | $3K | |
| Q3014 | Telehealth originating site facility fee | <1% | 89 | $2K |
| 70498 | <1% | 15 | $2K | |
| 73560 | <1% | 89 | $2K | |
| 0310 | <1% | 58 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 21 | $2K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 229 | $2K |
| 0300 | <1% | 234 | $2K | |
| 87400 | <1% | 271 | $2K | |
| 99218 | <1% | 19 | $2K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 350 | $2K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 260 | $2K |
| 84460 | <1% | 255 | $2K | |
| 85651 | <1% | 217 | $2K | |
| 84450 | <1% | 256 | $2K | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 79 | $2K |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 24 | $2K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 18 | $2K |
| 0420 | <1% | 21 | $1K | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 152 | $1K |
| 82565 | <1% | 210 | $1K | |
| 83550 | <1% | 620 | $1K | |
| 82378 | <1% | 190 | $1K | |
| 83540 | <1% | 672 | $1K | |
| 73140 | <1% | 39 | $937.37 | |
| 84145 | <1% | 41 | $899.36 | |
| 87522 | Neg quan hep c or qual rna | <1% | 13 | $845.68 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 13 | $747.18 |
| 73590 | <1% | 27 | $691.30 | |
| Z7502 | <1% | 17 | $688.20 | |
| 72020 | <1% | 29 | $678.82 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 105 | $637.59 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 60 | $610.27 |
| 82247 | <1% | 94 | $601.29 | |
| 73564 | <1% | 58 | $568.41 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 548 | $514.71 |
| 0255 | <1% | 17 | $496.67 | |
| 82550 | <1% | 64 | $434.66 | |
| 72070 | <1% | 14 | $429.20 | |
| 86140 | <1% | 60 | $380.07 | |
| 82248 | <1% | 53 | $328.75 | |
| 99221 | <1% | 12 | $308.88 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 120 | $247.96 |
| 84132 | <1% | 46 | $186.77 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 12 | $122.87 |
| 87088 | <1% | 12 | $106.84 | |
| 82607 | <1% | 50 | $84.08 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 13 | $47.92 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 101 | $26.20 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 16 | $1.44 |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | 0% | 20 | $0.00 |
| 84112 | 0% | 30 | $0.00 | |
| 0250R | 0% | 438 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGATES, JOHN (CFO)
| Provider | Location | Paid |
|---|---|---|
| Sutter Bay Hospitals | Castro Valley, CA | $52.65M |
| Sutter Bay Hospitals | Oakland, CA | $46.80M |
| Sutter Bay Hospitals | Lakeport, CA | $39.50M |
| Sutter Bay Hospitals | Santa Rosa, CA | $35.23M |
| Sutter Bay Hospitals | Antioch, CA | $29.48M |
| Sutter Bay Hospitals | San Francisco, CA | $19.99M |
| Sutter Bay Hospitals | Burlingame, CA | $17.15M |
| Sutter Bay Hospitals | San Francisco, CA | $14.94M |
| Sutter Bay Hospitals | Novato, CA | $11.12M |
| Sutter Bay Hospitals | San Francisco, CA | $6.79M |
| Sutter Bay Hospitals | Lakeport, CA | $3.99M |
| Sutter East Bay Hospitals | Antioch, CA | $3.45M |
| Sutter Bay Hospitals | Burlingame, CA | $1.98M |
| Sutter Bay Hospitals | Lakeport, CA | $1.72M |
| Sutter East Bay Hospitals | Oakland, CA | $1.10M |
| Sutter Bay Hospitals | San Francisco, CA | $1.08M |
| Sutter East Bay Hospitals | Berkeley, CA | $946K |
| Sutter West Bay Hospitals | San Francisco, CA | $186K |
| Magnetic Imaging Affiliates, LLC | Oakland, CA | $112K |
| Sutter Bay Hospitals | Berkeley, CA | $45K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.